Get the Stockscreener App
4.02
3.14%
-0.1305
Imagenebio Inc stock is traded at $4.02, with a volume of 18,237.
It is down -3.14% in the last 24 hours and down -18.29% over the past month.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
See More
Previous Close:
$4.1505
Open:
$4.26
24h Volume:
18,237
Relative Volume:
1.29
Market Cap:
$45.63M
Revenue:
$800.00K
Net Income/Loss:
$-45.07M
P/E Ratio:
-0.7645
EPS:
-5.2583
Net Cash Flow:
$-52.08M
1W Performance:
-5.63%
1M Performance:
-18.29%
6M Performance:
-28.85%
1Y Performance:
-47.31%
1-Day Range:
$3.982
$4.26
1-Week Range:
$3.90
$4.31
52-Week Range:
$3.90
$9.10
Imagenebio Inc Stock (IMA) Company Profile
Name
Imagenebio Inc
Sector
Industry
Phone
857-343-8292
Address
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
4.02 | 45.63M | 800.00K | -45.07M | -52.08M | -5.2583 |
VRTX
Vertex Pharmaceuticals Inc
|
508.15 | 128.80B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.82 | 95.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.63 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.39 | 53.54B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.90 | 42.30B | 5.76B | 514.49M | 1.10B | 4.4813 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-26 | Initiated | H.C. Wainwright | Buy |
| Nov-25-25 | Resumed | Wedbush | Underperform |
| Oct-24-25 | Initiated | Leerink Partners | Outperform |
Imagenebio Inc Stock (IMA) Latest News
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires receive ImageneBio stock awards; options let them buy shares for $4.58 - Stock Titan
ImageneBio, Inc. (NASDAQ: IMA) Share Price, IMA Stock News, IMA Share Price & Updates - kalkine.com.au
ImageneBio, Inc.Common Stock (Nasdaq:IMA) Detailed Stock Data - The Chronicle-Journal
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York - The Manila Times
A biotech CEO will speak in New York. ImageneBio will archive the webcast for 90 days. - Stock Titan
IMA Q2 2026 Earnings: Narrower EPS Loss Beats Estimates, Shares Slip 6.4%Earnings Call Highlights - vinanet.vn
ImageneBio (IMA) Edges Higher to $5.34 as Bulls Defend Key SupportPost-Earnings Moves - vinanet.vn
ImageneBio (IMA) Edges Higher to $5.34 as Bulls Defend Key SupportVol Target Rebalance - dars.gov.et
ImageneBio (IMA) Market: Finishes 1.78% Lower at $5.51 in the Current Update; Technical View: the Price Remains Bounded by the Supplied Support and Resistance on the DayCorrective Wave - vinanet.vn
ImageneBio (IMA) Market: Finishes 1.78% Lower at $5.51 in the Current Update; Technical View: the Price Remains Bounded by the Supplied Support and Resistance on the DayIV Crush Alert - dars.gov.et
ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
HC Wainwright Initiates ImageneBio at Buy With $28 Price Target - marketscreener.com
Blue Owl Capital Holdings LP Invests $5.41 Million in ImageneBio, Inc. $IMA - MarketBeat
ImageneBio (NASDAQ:IMA) Trading 1.8% HigherWhat's Next? - MarketBeat
ImageneBio Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ImageneBio (IMA) shifts CFO equity mix toward RSUs in new grant - Stock Titan
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
ImageneBio's New Hires Get Stock Awards as CFO Gets a Separate Award - Stock Titan
ImageneBio, Inc. (IMA): BVF group discloses 9.99% stake and large warrants - Stock Titan
ImageneBio, Inc. (NASDAQ: IMA) Share Price, IMA Stock News, IMA Share Price & Updates - kalkine.ca
ImageneBio, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
ImageneBio, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
ImageneBio Ord Shs (IMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ImageneBio, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Wedbush Maintains ImageneBio(IMA.US) With Sell Rating, Maintains Target Price $2 - Moomoo
William Blair Maintains ImageneBio(IMA.US) With Buy Rating - Moomoo
ImageneBio (IMA) registers 1.37M existing shares for resale on Form S-3 - Stock Titan
ImageneBio (IMA) sets up $200M shelf and $17M ATM stock program - Stock Titan
ImageneBio (IMA) files to register 5.77M warrant shares for investor resale - Stock Titan
ImageneBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ImageneBio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ImageneBio Sees Cash Runway Funding Planned Ops Into 1Q of 2028 >IMA - Moomoo
ImageneBio, Inc. Q2 2026: Revenue $0 EPS $(0.63) — 10-Q Summary - TradingView
ImageneBio Reports Second Quarter 2026 Financial Results - The Manila Times
ImageneBio Reports Second Quarter 2026 Financial Results and Corporate Update on Olevaprubart Clinical Development - Quiver Quantitative
ImageneBio reports Q2 2026: $136.2M cash; $10.2M net loss for quarter - TradingView
ImageneBio Posts $10.2 Million Q2 Loss With Cash Runway Into 2028 - Quiver Quantitative
ImageneBio (Nasdaq: IMA) details Q2 2026 loss and $136M cash runway - Stock Titan
IMA: Clinical pipeline advances and robust cash position support continued development through 2028 - TradingView
ImageneBio Sees Cash Runway Funding Planned Ops Into 1Q of 2028 >IMA - Moomoo
ImageneBio’s Atopic Dermatitis Data Anticipated in Q4 2027 - Stock Titan
ImageneBio Posts $10.2 Million Q2 Loss With Cash Runway Into 2028 - Quiver Quantitative
IKNA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
IMA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ImageneBio, Inc. Revenue Breakdown – NASDAQ:IMA - TradingView
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Miss Highlights Pre‑Revenue Challenges as Stock Rises - dars.gov.et
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Miss Highlights Pre‑Revenue Challenges as Stock Rises - dars.gov.et
Imagenebio Inc Stock (IMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Imagenebio Inc Stock (IMA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lally Robert B | Principal Accounting Officer |
Jul 17 '26 |
Sale |
5.34 |
1,525 |
8,144 |
55,582 |
| Lally Robert B | Principal Accounting Officer |
Jul 16 '26 |
Sale |
5.50 |
1,671 |
9,190 |
57,107 |
| SLATTERY JOSEPH P | Director |
Dec 24 '25 |
Buy |
5.99 |
16,000 |
95,840 |
16,000 |
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):